ACLY and fetal growth restriction: Previous studies have shown that aβ2GP1 and aCL antibodies are strongly associated with preeclampsia, and reducing these antibody levels through treatment can significantly lower the risks of fetal growth restriction (FGR), intrauterine fetal distress, and preterm birth (Hanieh et al., 2019; Aline et al., 2010).